Authors

• Catherine Fernandez (ORCID: https://orcid.org/0000-0001-8561-5642)
• Linda D. Sharples (ORCID: https://orcid.org/0000-0003-0894-966X)
• Andrew T. Yan (ORCID: https://orcid.org/0000-0002-2063-7485)
• Ramesh Nadarajah (ORCID: https://orcid.org/0000-0001-9895-9356)
• Deborah D. Stocken (ORCID: https://orcid.org/0000-0001-8031-1738)
• Derek P. Chew (ORCID: https://orcid.org/0000-0003-3593-296X)
• Keith A.A. Fox (ORCID: https://orcid.org/0000-0002-0140-2752)
• David Brieger (ORCID: https://orcid.org/0000-0001-6115-0326)
• Shaun G. Goodman (ORCID: https://orcid.org/0000-0001-8068-2440)
• Chris P Gale (ORCID: https://orcid.org/0000-0003-4732-382X)
• Rachael Gilberts (ORCID: https://orcid.org/0000-0003-3326-7900)
• Suleman Aktaa (ORCID: https://orcid.org/0000-0002-9854-481X)
• Kathryn Carruthers (ORCID: https://orcid.org/0000-0002-5896-2339)
• Catherine Reynolds

Institutions

• St. Michael's Hospital (CA)
• University of Leeds (GB)
• University of Alberta (CA)
• University of Toronto (CA)
• Leeds Teaching Hospitals NHS Trust (GB)
• Concord Repatriation General Hospital (AU)
• Edinburgh Royal Infirmary (GB)
• London School of Hygiene & Tropical Medicine (GB)
• Monash Health (AU)
• Australian Centre for Heart Health (AU)
• University of Edinburgh (GB)

Publication Details

Journal

Open Heart

Published

2025-01-01

DOI

https://doi.org/10.1136/openhrt-2025-003213

Primary Topic

Acute Myocardial Infarction Research

Type

article

Field-Weighted Citation Impact

0.00

Funders

• Amgen
• Bristol-Myers Squibb
• Eli Lilly and Company
• Pfizer
• AstraZeneca
• National Institute for Health and Care Research
• British Heart Foundation
• European Society of Cardiology
• Daiichi-Sankyo
• Vifor Pharma